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Abstract
The purpose of the present study was to evaluate the signiﬁcance of shortening the antibiotic treatment duration in prosthetic joint
infections (PJI) treated with debridement, antibiotics and implant retention (DAIR). In April 2006 we shortened the total antibiotic treat-
ment duration in total knee arthroplasty (TKA) PJIs from 6 months to 3 months and in total hip arthroplasty (THA) PJIs from 3 months
to 2 months. All patients with TKA or THA PJI treated with DAIR between February 2001 and August 2009 were reviewed retrospec-
tively. There were 132 patients treated with DAIR, of whom 86 (65%) completed the antibiotic therapy and were therefore eligible for
comparison concerning the length of antibiotic treatment. There were 32 (37%) THA and 54 (63%) TKA PJIs in the comparison. The
treatment succeeded in 34 (89.5%) patients treated with longer antibiotic treatment and in 42 (87.5%) of those treated with shorter
antibiotic treatment (p 0.78). Our conclusion is that if the patient completes the antibiotic therapy, treatment duration of 3 months in
TKA PJIs and 2 months in THA PJIs is as good as longer antibiotic treatment of 6 months or 3 months, respectively, in patients treated
with DAIR.
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Introduction
The need for total arthroplasties has been rising since the
1990s. Even though prosthetic joint infections (PJI) are an
infrequent complication, occurring in 0.57–5.6% of the cases
[1,2], their treatment is laborious and expensive for both the
patient and society. It has been reported that 18–84% of PJIs
can be treated with debridement, antibiotics and implant
retention (DAIR) [3–5], which is less stressful to the patient
and is associated with less morbidity than two-stage
exchange [6], but on the other hand it requires prolonged
antibiotic treatment. Sixteen per cent of patients have been
described as having antibiotic-related complications when
treating chronic bone infections [7]. There is also evidence
that long-term exposure to antibiotics will increase cumula-
tive dose-related adverse events [8].
The optimal antibiotic treatment (the choice and duration)
of PJIs is not known. According to a widely used algorithm
suggested by a Swiss group [9–11], the duration of antibiotic
treatment is 6 months for total knee arthroplasty (TKA) PJIs
and 3 months for total hip arthroplasty (THA) PJIs treated
with DAIR. In some recent studies, it has been reported that
a shorter course of antibiotics is also an alternative in DAIR
treatment [4,12–16].
In April 2006 we shortened the antibiotic treatment dura-
tion in PJI patients treated with DAIR to 3 months for TKA
PJIs and 2 months for THA PJIs. In this study, we compare
the outcomes of the previous longer and the current shorter
antibiotic treatments.
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Materials and Methods
The study was carried out in Oulu University Hospital, which
is a tertiary-level teaching hospital with 900 beds in northern
Finland serving 390 000 people. There are three hospitals
performing primary total arthroplasties in the district. The
revision surgery and infection complications are managed in
the Oulu University Hospital. PJIs are treated by a clinical
team comprising infectious disease physicians and orthopae-
dic surgeons. The ethical committee of the hospital approved
the study.
In our hospital the antibiotic treatment duration in DAIR
was modiﬁed in April 2006. Before April 2006 TKA PJIs
treated with DAIR received 6 months and THA PJIs received
3 months of antibiotics according to the suggestion of
Zimmerli et al. [17] in 1998 (longer antibiotic treatment).
Since April 2006 the duration of antibiotic treatment has
been reduced to 3 months for TKA PJIs and 2 months for
THA PJIs (shorter antibiotic treatment).
The study population comprised patients with PJI who
underwent DAIR for the ﬁrst time between February 2001
and August 2009. All patients with PJI who were treated during
the study period were reviewed retrospectively. We excluded
patients who were referred directly to two-stage exchange
and patients who were lost from follow-up, who died of non-
infectious causes before completing the treatment or who
were given permanent suppressive treatment when operative
treatment was not possible. The end of follow-up was deﬁned
as the latest control visit concerning the treated PJI.
The PJI was deﬁned as having (a) growth of the same
micro-organism in two or more cultures of synovial ﬂuid or
periprosthetic tissue, (b) purulence at the implant site at
operation or (c) sinus tract [9]. The patient was considered
to have undergone DAIR treatment if the ﬁrst operation after
suspecting an infection was debridement, even if the patient
was referred to two-stage exchange surgery within the next
few days upon consultation with a senior orthopaedic surgeon.
Treatment failure was deﬁned if (a) the patient was
referred to two-stage exchange surgery at any time during
treatment or follow-up, (b) the patient had symptoms or
signs of infection after the end of antibiotic treatment or (c)
the patient was referred to permanent suppressive antibiotic
treatment. Treatment success was achieved if the original
prosthesis was retained and the patient had no symptoms or
signs of infection and C-reactive protein and sedimentation
rate were normal at the end of follow-up.
For intention-to-treat (ITT) analysis we included the com-
plete study population (patients who were referred to DAIR).
In the per protocol (PP) analysis we included patients who
completed the antibiotic treatment and outcome assessment
that started at the end of the antibiotic treatment course.
We collected patient data from medical records on age,
gender, co-morbidities, body mass index (BMI), American
Society of Anesthesia scores, anticoagulant medication, type
of implant, the date of primary and previous surgery, symp-
toms, symptom onset, C-reactive protein, sedimentation
rate, leucocyte count, blood cultures, antibiotic duration
(intravenous and oral), microbiological culture results and out-
come. The type of infection was classiﬁed as early postopera-
tive (£30 days after operation), acute haematogenous (acute
onset of symptoms in previously asymptomatic joint with a
documented or suspected antecedent bacteraemia and symp-
tom duration £30 days) and chronic (postoperative infection
diagnosed >30 days after operation or haematogenous infec-
tion with symptom onset >30 days ago) [18,19].
The normal procedure in our hospital in suspected cases of
PJI is to start antimicrobial treatment after obtaining the micro-
biological samples at surgical debridement. The antibiotics are
started with a combination of vancomycin and cefuroxime,
which are modiﬁed according to the microbiological culture
results. In PJIs caused by gram-positive bacteria, except entero-
cocci, rifampicin is always used in the treatment if the species is
sensitive. If the infection is caused by Staphylococcus aureus
(methicillin-sensitive) or streptococci, we use cefuroxime
combined with rifampicin. For coagulase-negative staphylo-
cocci and methicillin-resistant S. aureus, vancomycin is com-
bined with rifampicin. The duration of the intravenous
antibiotic treatment is 4 weeks. Part of the intravenous antibi-
otic administration can be conducted through outpatient par-
enteral antimicrobial treatment, if the recovery is favourable.
The subsequent oral treatment for staphylococcus species is
rifampicin and ﬂuoroquinolone, if the species is sensitive. For
rifampicin-resistant or ﬂuoroquinolone-resistant bacteria we
also use combinations of clindamycin and fucidinic acid or lin-
ezolide alone. For gram-negative bacteria the intravenous anti-
biotic treatment is prescribed according to sensitivity, followed
by oral ﬂuoroquinolone if sensitive. If there is no oral antibiotic
treatment regimen (for example resistant organism or patient’s
allergy), the antibiotic treatment is conducted intravenously
through outpatient parenteral antimicrobial treatment.
The surgical treatment strategy has been similar during
the study period: the debridement is performed carefully and
the exposed tissue surfaces are irrigated with sterile saline
using pulsed lavage. Intraoperative microbiological samples
are taken from four to six places. Any modular prosthesis
components are exchanged when possible. Wounds are
closed primarily and no drains are used.
Statistical analysis was performed using SPSS software
v.19.0 (IBM, Armonk, NY, USA). Categorical variables were
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compared by the chi-square test or Fisher’s exact test when
necessary, and continuous variables were compared with
Students t-test or analysis of variance.
Results
In all, 197 patients had PJI during the study period; 95
patients had previously undergone arthroplastic surgery in
Oulu University Hospital and the remaining 102 patients had
been operated on at other hospitals. The incidence of infec-
tion in our hospital was 1.9% (61/3198) in primary total
arthroplastic surgery and 2.4% (34/1439) in revision arthro-
plastic surgery. Sixty-ﬁve patients were ineligible for the fol-
lowing reasons: 56 patients were treated directly with two-
stage exchange, four were lost from follow-up, one died
from non-infectious causes before completing the antibiotic
treatment and four were given permanent suppressive treat-
ment when operative treatment was not possible.
The study population consisted of 132 patients (ITT
group); 60 patients in the longer antibiotic treatment group
and 72 in the shorter antibiotic treatment groups. The DAIR
treatment was unsuccessful in 46 (35%) patients (22 in the
longer antibiotic group and 24 in the shorter antibiotic
group) before completing the antibiotic treatment, and con-
sequently they were excluded from the PP analysis.
There were 86 patients in the PP analysis; 38 (44%) PJIs
(27 TKA and 11 THA) in the longer antibiotic treatment and
48 (56%) PJIs (27 TKA and 21 THA) in the shorter antibiotic
treatment group. There were 31 revision arthroplasty
patients: 21 THAs (5 and 16, respectively in different groups)
and 10 TKAs (ﬁve in each group). Fifty-seven (66%) were
early postoperative infections, 20 (23%) were acute haemat-
ogenous infections and 9 (11%) were chronic infections. The
mean times of follow-up for the longer and shorter treat-
ments were 50.6 (SD 29) months and 26.2 (SD 12) months,
respectively. The patient characteristics in both ITT and PP
analyses are presented in Table 1.
TABLE 1. The demographics of the patients
Intention-to-treat analysis Per protocol analysis
Long antibiotic
treatment
2/2001–3/2006
(n = 60)
Short antibiotic
treatment
4/2006–8/2009
(n = 72) p
Long antibiotic
treatment
2/2001–3/2006
(n = 38)
Short antibiotic
treatment
4/2006 – 8/2009
(n = 48) p
Age, mean ± SD 67 ± 10.0 69 ± 10.2 0.28 65 ± 9.9 70 ± 10.4 0.033
Male 29 (48%) 31 (43%) 0.54 18 (47%) 21 (44%) 0.74
Type of prosthesis
TKA 40 (67%) 37 (51%) 0.08 27 (71%) 27 (56%) 0.29
THA 20 (33%) 35 (49%) 0.08 11 (29%) 21 (44%) 0.16
Revision 10 (17%) 21 (29%) 0.13 6 (16%) 14 (29%) 0.15
BMI, mean ± SD 31 ± 6.5 32 ± 7.0 0.44 31 ± 7.5 31 ± 6.6 0.7
ASA, mean ± SD 2.7 ± 0.5 2.8 ± 0.5 0.21 2.7 ± 0.6 2.9 ± 0.5 0.1
Diabetes mellitus 13 (22%) 17 (24%) 0.79 6 (16%) 13 (27%) 0.21
Rheumatoid arthritis 13 (22%) 7 (10%) 0.046 9 (25%) 7 (15%) 0.23
Anticoagulant treatment (warfarin) 13 (22%) 14 (19%) 0.75 10 (26%) 10 (21%) 0.55
Type of infection
Early postoperativea 32 (53%) 44 (61%) 0.37 22 (58%) 35 (73%) 0.14
Acute haematogenousb 18 (30%) 17 (24%) 0.41 11 (29%) 9 (19%) 0.27
Chronicc 10 (17%) 11 (15%) 0.83 5 (13%) 4 (8%) 0.47
Duration of symptoms, days, median
(25th–75th percentile)
4 (2–10) 4 (2–7) 0.47 5.5 (3–10) 4 (2–7) 0.7
Sinus tract 8 (13%) 3 (4%) 0.058 6 (16%) 1 (2%) 0.02
CRP, mg/l, median (25th–75th percentile) 107 (38–228) 51 (20–180) 0.043 76 (34–243) 36.5 (19–190) 0.145
Leukocyte count, 109 cells/l, median
(25th–75th percentile)
10.2 (7.3–14.4) 8.8 (7–11.9) 0.28 8.8 (6.4–13.3) 8.7 (6.7–10.3) 0.28
Body temperature, C, mean 37.8 ± 1.3 37.3 ± 0.7 0.007 37.4 ± 1.2 37.2 ± 0.6 0.32
Positive microbiological culture in the
ﬁrst debridement
55 (93%) 67 (94%) 0.79 34 (92%) 46 (96%) 0.44
Positive blood culture 10 (17%) 14 (19%) 0.69 7 (18%) 7 (15%) 0.60
Follow-up time, months, median
(25th–75th percentile)
41.5 (18–62) 18 (15–29) <0.001 53.5 (20–71) 22.5 (15–37) <0.001
Failure 26 (43%) 30 (42%) 0.85 4 (11%) 6 (13%) 0.78
TKA 16 (40%) 14 (39%) 0.85 3 (11%) 4 (15%) 0.5
THA 10 (50%) 16 (46%) 0.76 1 (9%) 2 (10%) 0.73
Antibiotic treatment duration, days,
median (25th–75th percentile)
NR NR 171.5 (88–189) 88 (63–92) <0.001
TKA NR NR 181 (166–194) 92 (89–97) 0.002
THA NR NR 87 (48–115) 61 (58–69) 0.01
a£1 month since the operation.
bAcute onset of symptoms in previously asymptomatic joint with a documented or suspected antecedent bacteraemia and symptoms duration £30 days.
cPostoperative infection diagnosed >30 days after operation or haematogenous infection with symptom onset >30 days.
TKA, total knee arthroplasty; THA, total hip arthroplasty; BMI, body mass index; ASA, American Society of Anesthesia scores; NR, not relevant.
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There were no signiﬁcant differences in microbiology
between longer and shorter treatment groups in either the
ITT or PP analyses; in the ITT group, there were altogether
35 (27% of the patients) coagulase-negative staphylococci, 56
(42%) S. aureus (one methicillin-resistant), 29 (22%) strepto-
cocci, 17 (13%) gram-negative rods, 20 (15%) other
microbes. Twenty-one (16%) infections were polymicrobial.
The treatment success in ITT analysis (132 patients)
was 56.7% in the longer antibiotic treatment group and
58.3% in the shorter antibiotic treatment group (p 0.85).
In the PP analysis, the treatment success was 89.5% in
patients treated with longer antibiotic treatment and 87.5%
in patients treated with shorter antibiotic treatment
(p 0.78). Ten patients failed after the antibiotic treatment
was completed: four (10.5%) patients in the longer treat-
ment group and six (12.5%) in the shorter treatment
group. The four failed patients in the longer treatment
had at least one of the following factors: two patients had
chronic infection, one patient had a BMI of 43, one had
very short antibiotic treatment (48 days for THA) together
with severe coronary heart disease and Enterobacter cloacae
infection, and one had infection caused by Pseudomonas.
The six failed patients in the shorter treatment group had
one or more of the following factors: one had chronic
infection, one had chronic lymphatic leukaemia, two had
severe obliterative arteriosclerosis leading to amputation,
two had severe coronary heart disease and one had
severe coronary heart disease with a very short antibiotic
treatment (42 days for THA). The median time to antibi-
otic treatment failure in ITT analysis was 17 days (75th
percentile 30 days) for THA PJIs and 23 days (75th per-
centile 78 days) for TKA PJIs.
Discussion
Our results show that if the planned antibiotic treatment in
PJIs can be completed, then the DAIR treatment results are
excellent (88%), and prolonging the antibiotic treatment over
3 months in TKA PJIS and 2 months in THA PJIs does not
seem to give any beneﬁt.
Our study has several strengths. It describes actual clinical
practice and patients with different conditions and co-mor-
bidities affecting the choice of treatment strategy. For this
reason, some patients with chronic infection were treated
‘erroneously’ with DAIR. The time limit of chronic infection
in our study was set at 30 days, but in clinical practice the
time limit was more ﬂexible and the decision on the ﬁrst
operation was often made by the orthopaedic surgeon in
charge. Moreover, in some chronic PJIs the two-stage
exchange was not used either because of the patient’s under-
lying co-morbidities or because the surgery would have been
technically extremely difﬁcult to perform. It has been shown
earlier that most patients will fail within 4 months after the
end of antibiotic treatment [20]. Because the follow-up in
our study was exceptionally long in both the longer
(>3 years) and shorter (almost 2 years) treatment groups,
the failures were reliably identiﬁed. This is further supported
by the fact that our unit treats all of these infection compli-
cations in the district.
On the other hand, our study also has some weaknesses.
It was retrospective and the study population was heteroge-
neous. The failure rate in DAIR in the ITT analysis was high.
This can be explained by at least two factors. First, we
included both chronic and haematogenic infections in our
series. Second, we had patients who underwent one debride-
ment operation as the result of the decision of the ortho-
paedic surgeon in charge, but who were very soon referred
to two-stage exchange upon consultation with a senior
orthopaedic surgeon.
Variable treatment success rates (14–100%) with DAIR
have been achieved earlier with long antibiotic treatment
depending on the type of infection and patient characteris-
tics, which indicate the great heterogeneity in the published
studies [5,9,10,20,21]. Recent studies have suggested that
successful outcome can be achieved also with shorter antibi-
otic treatment [4,12–16]. It is interesting that in short antibi-
otic treatment studies the success rate has varied less than
in long treatment studies, probably because of the more
accurate patient selection. The success rate has been 57–
83% in short treatment studies, which are presented in
Table 2. One of these studies had a success rate of 57%,
because one of the nine participating hospitals had clearly
worse outcome than the other eight hospitals. In a British
study it was demonstrated that lengthening the antibiotic
therapy might simply postpone rather than prevent the fail-
ure. However, the mean duration of antibiotics was 1.5 years
in that study [20]. In our study the patients who failed had
several risk factors (chronic infection, severe underlying dis-
ease or severe obesity), which underscore the importance of
careful patient selection for DAIR.
In summary, short antibiotic treatment seems to be a
good alternative for PJIs treated with DAIR. The optimal
antibiotic treatment duration in DAIR treatment remains
unknown. In addition, there is no evidence that TKA PJIs
would need a longer course of antibiotics than THA PJIs. To
conﬁrm the promising results of this retrospective study,
prospective randomized controlled trials are urgently needed
to resolve the optimal duration of antibiotic treatment in
DAIR.
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